Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Abstract

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.

Keywords

• Keywords: antiviral agents
• disease outbreaks
• Influenza
• Prevention and Control
• Cost-Benefit Analysis
• Israel